DYRK2
Summary: DYRK2 belongs to a family of protein kinases whose members are presumed to be involved in cellular growth and/or development. The family is defined by structural similarity of their kinase domains and their capability to autophosphorylate on tyrosine residues. DYRK2 has demonstrated tyrosine autophosphorylation and catalyzed phosphorylation of histones H3 and H2B in vitro. Two isoforms of DYRK2 have been isolated. The predominant isoform, isoform 1, lacks a 5' terminal insert. [provided by RefSeq, Jul 2008].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
dual specificity tyrosine phosphorylation regulated kinase 2 | MIM:603496 | Ensembl:ENSG00000127334 | HGNC:HGNC:3093 | PA27550 | 12q15 |
GO terms in DYRK2
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
BP | IDA | GO:0006468 | protein phosphorylation |
BP | IEP | GO:0006974 | cellular response to DNA damage stimulus |
BP | IMP | GO:0007224 | smoothened signaling pathway |
BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
BP | IDA | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator |
BP | IDA | GO:0045725 | positive regulation of glycogen biosynthetic process |
BP | IMP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade |
BP | TAS | GO:1901796 | regulation of signal transduction by p53 class mediator |
CC | IDA | GO:0000151 | ubiquitin ligase complex |
CC | IDA | GO:0005634 | nucleus |
CC | IDA | GO:0005654 | nucleoplasm |
CC | TAS | GO:0005654 | nucleoplasm |
CC | IDA | GO:0005737 | cytoplasm |
CC | IDA | GO:0005829 | cytosol |
CC | IEA | GO:1990904 | ribonucleoprotein complex |
MF | IDA | GO:0000287 | magnesium ion binding |
MF | IDA | GO:0004674 | protein serine/threonine kinase activity |
MF | TAS | GO:0004674 | protein serine/threonine kinase activity |
MF | IEA | GO:0004712 | protein serine/threonine/tyrosine kinase activity |
MF | IDA | GO:0004713 | protein tyrosine kinase activity |
MF | IPI | GO:0005515 | protein binding |
MF | IDA | GO:0005524 | ATP binding |
MF | IDA | GO:0030145 | manganese ion binding |
Gene expression in normal tissue: DYRK2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in DYRK2
Database | Pathway ID | Pathway Des. |
---|---|---|
reactome | R-HSA-212436 | Generic Transcription Pathway |
reactome | R-HSA-3700989 | Transcriptional Regulation by TP53 |
reactome | R-HSA-5633007 | Regulation of TP53 Activity |
reactome | R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation |
reactome | R-HSA-73857 | RNA Polymerase II Transcription |
reactome | R-HSA-74160 | Gene expression (Transcription) |
pid | p53regulationpathway | p53 pathway |
wikipathways | WP2583 | T-Cell Receptor and Co-stimulatory Signaling |
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD560 | MK-2206 | 3 |
iGMDRD148 | Pifithrin-mu | 2 |
iGMDRD154 | NSC23766 | 1 |
iGMDRD132 | (-)-gallocatechin-3-O-gallate | 5 |
iGMDRD211 | (1S,3R)-RSL3 | 2 |
iGMDRD219 | Bax channel blocker | 2 |
iGMDRD341 | Triacsin c | 2 |
iGMDRD705 | Nakiterpiosin | 1 |
iGMDRD105 | Triptolide | 5 |
iGMDRD121 | GMX1778 | 1 |
iGMDRD251 | ML162 | 1 |
iGMDRD322 | FK 866 | 1 |
iGMDRD886 | Compound 1541A | 1 |
iGMDRD505 | Pevonedistat | 6 |
iGMDRD329 | Merck60 | 5 |
iGMDRD286 | Nsc 632839 | 2 |
iGMDRD494 | Neopeltolide | 6 |
iGMDRD670 | ML 210 | 2 |
iGMDRD427 | ABT737 | 1 |
iGMDRD420 | Leucascandrolide A | 6 |
iGMDRD634 | SCHEMBL2608041 | 2 |
iGMDRD280 | CYTOCHALASIN B | 4 |
iGMDRD466 | Chaetocin | 1 |
iGMDRD152 | 179324-69-7 | 3 |
iGMDRD446 | LY 2183240 | 3 |
iGMDRD318 | PAC-1 | 5 |
iGMDRD870 | BRD63610 | 6 |
iGMDRD52 | Rotenone | 4 |
iGMDRD782 | DC-45-A2 | 4 |
iGMDRD255 | SB225002 | 3 |
iGMDRD474 | Avrainvillamide | 1 |
iGMDRD23 | Gossypol | 5 |
iGMDRD562 | Navitoclax | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in DYRK2